- News Releases - CSL
About CSL Behring CSL Behring is a global biotherapeutics leader driven by its promise to save lives Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders
- Worldwide Locations - CSL
Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe
- Global Biotechnology Company - CSL
CSL Behring is a global biotherapeutics leader driven by our promise to save lives Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas
- Global Biotechnology Company | CSL
CSL Always Evolving for a Better World CSL has delivered biotechnology excellence for over a century Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need
- Area Manager, Specialty West jobs near me in Sellersville, PA, US at CSL
CSL Associates is hiring Area Manager, Specialty West View more CSL Associates jobs in Sellersville, PA, US,18960 and apply now
- Associate Director, US Payer Marketing - jobiak. csl. com
Job Description The Associate Director of US Payer Marketing will lead US value, access, and reimbursement strategy for the launch of CSL Behring’s pipeline assets
- Expanding Cell- and Gene-Therapy Capability in the U. S. - CSL
Driven by its promise to patients, CSL Behring is expanding the company's U S hub for cell- and gene-therapy in Pasadena, California, with added lab and office space to enhance innovation
- U. S. Food and Drug Administration Approves CSLs ANDEMBRY® (garadacimab . . .
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89 2 percent, compared to placebo ANDEMBRY approval expands CSL's HAE franchise
|